Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI1873 in advanced solid tumors
NCT02583165Phase 1Completed
- Sponsor
- MedImmune
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of efgivanermin alfa in solid tumor (advanced stage), sponsored by MedImmune. Primary endpoints: Adverse Events at 12 months, Serious Adverse Events at 12 months and 1 more. Started Nov 2015; status: completed.
02
Drugs
efgivanermin alfa
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02583165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02583165.